|
Gene: RMDN2 |
Gene summary for RMDN2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RMDN2 | Gene ID | 151393 |
Gene name | regulator of microtubule dynamics 2 | |
Gene Alias | BLOCK18 | |
Cytomap | 2p22.2 | |
Gene Type | protein-coding | GO ID | GO:0000922 | UniProtAcc | Q96LZ7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
151393 | RMDN2 | A002-C-116 | Human | Colorectum | FAP | 8.76e-25 | -4.36e-01 | -0.0452 |
151393 | RMDN2 | A014-C-008 | Human | Colorectum | FAP | 3.24e-10 | -4.83e-01 | -0.191 |
151393 | RMDN2 | A018-E-020 | Human | Colorectum | FAP | 2.00e-12 | -4.49e-01 | -0.2034 |
151393 | RMDN2 | F034 | Human | Colorectum | FAP | 5.25e-25 | -5.22e-01 | -0.0665 |
151393 | RMDN2 | F072B | Human | Colorectum | FAP | 1.16e-11 | -3.42e-01 | 0.257 |
151393 | RMDN2 | CRC-1-8810 | Human | Colorectum | CRC | 7.79e-04 | -2.59e-01 | 0.6257 |
151393 | RMDN2 | CRC-3-11773 | Human | Colorectum | CRC | 5.44e-18 | -4.91e-01 | 0.2564 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RMDN2 | SNV | Missense_Mutation | novel | c.689N>A | p.Gly230Glu | p.G230E | protein_coding | tolerated_low_confidence(0.71) | benign(0.099) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RMDN2 | SNV | Missense_Mutation | c.62N>G | p.Asp21Gly | p.D21G | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.638) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
RMDN2 | SNV | Missense_Mutation | c.1240N>C | p.Glu414Gln | p.E414Q | protein_coding | deleterious(0.03) | probably_damaging(0.918) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | ||
RMDN2 | insertion | Frame_Shift_Ins | novel | c.1599_1600insGATATTCCTAGGACAAGTCCTA | p.Tyr534AspfsTer10 | p.Y534Dfs*10 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | |||
RMDN2 | SNV | Missense_Mutation | c.1279G>A | p.Glu427Lys | p.E427K | protein_coding | tolerated(0.13) | benign(0.444) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
RMDN2 | SNV | Missense_Mutation | novel | c.227N>A | p.Arg76Lys | p.R76K | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.488) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
RMDN2 | SNV | Missense_Mutation | c.959N>A | p.Ser320Tyr | p.S320Y | protein_coding | deleterious(0.01) | benign(0.413) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | ||
RMDN2 | SNV | Missense_Mutation | rs776380587 | c.1245G>T | p.Lys415Asn | p.K415N | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
RMDN2 | SNV | Missense_Mutation | novel | c.293N>C | p.Glu98Ala | p.E98A | Q96LZ7 | protein_coding | tolerated(0.07) | possibly_damaging(0.88) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
RMDN2 | SNV | Missense_Mutation | novel | c.556N>C | p.Asn186His | p.N186H | protein_coding | tolerated_low_confidence(1) | benign(0.006) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |